Industry News
Biotechnology Industry News
Roche has headed back to China to…
Roche has headed back to China to pen a licensing deal worth more than $1 billion biobucks for the rights to a clinical-stage bispecific antibody for respiratory diseases.
Roche’s Genentech unit is laying…
Roche’s Genentech unit is laying off staff at its Bay Area headquarters for the third time this year, saying goodbye to 118 employees in a workforce reduction that spans multiple departments.
SVP David Burnham outlines how…
SVP David Burnham outlines how payer engagement, digital innovation and patient-centric design are reshaping clinical trials and accelerating development timelines.
Startup’s hybrid AI system aims…
Startup’s hybrid AI system aims to reduce documentation bottlenecks and accelerate drug development timelines across the pharmaceutical industry.
AbbVie has scrapped an asset from…
AbbVie has scrapped an asset from its ongoing collaboration with Dragonfly Therapeutics, a spokesperson for the Chicago pharma confirmed to Fierce Biotech.
Novartis is pulling back the…
Novartis is pulling back the curtain on late-stage Sjögren’s wins, revealing an edge for its investigational monoclonal antibody ianalumab over placebo in both studies.
Regeneron is buying into Modex…
Regeneron is buying into Modex Therapeutics’ next-generation antibody platform with a $7 million upfront payment and a total potential deal value exceeding $1 billion.
Amgen Ventures-backed AAVantgarde…
Amgen Ventures-backed AAVantgarde Bio has raised $143 million in series B funding that the Italian biotech will use to push its two AAV gene therapies for eye diseases through the clinic.
Kyverna Therapeutics has reported…
Kyverna Therapeutics has reported deep, sustained improvements in autoimmune disease patients who received a single dose of its CAR T-cell therapy KYV-101.
GSK once dreamed of harnessing the…
GSK once dreamed of harnessing the CD226 axis to create a new generation of blockbuster cancer drugs. But that dream appeared to die this morning as the pharma closed the last programs related to this
BridgeBio Pharma is having a…
BridgeBio Pharma is having a banner week, with the Bay Area company’s encaleret acing a phase 3 trial just days after another late-stage rare disease win as it eyes an FDA review in 2026.
Eli Lilly and computing giant…
Eli Lilly and computing giant Nvidia are teaming up to build a new supercomputer that the pair say will be the most powerful owned and operated by a pharmaceutical company.
Edesa Biotech has shared data from…
Edesa Biotech has shared data from its truncated phase 3 respiratory failure trial, linking the anti-TLR4 antibody to improvements in survival and recovery.
Aldeyra Therapeutics has shaken up…
Aldeyra Therapeutics has shaken up its drug development pipeline, stopping work on one asset in the wake of phase 2 data and swapping out two other molecules in response to recent results.
Incyte’s decision to scrap work…
Incyte’s decision to scrap work on its BET inhibitor program has not surprised analysts, who pointed to safety concerns overshadowing the drug class.
GSK’s antibody-drug conjugate…
GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about oligonucleotides.
With a new approach to creating…
With a new approach to creating thymus-targeted medicines to treat and prevent autoimmune diseases, Zag Bio has emerged from stealth with the help of backing from biopharma giants AbbVie, Regeneron and Sanofi.
Late-stage ovarian cancer trials…
Late-stage ovarian cancer trials face unique hurdles. Learn how new feasibility planning can turn risk into readiness.
The number of biopharma M&A…
The number of biopharma M&A deals announced so far this year is higher than the yearly average for the last 15 years, while deal value has already eclipsed last year’s total, according to a recent
Intellia Therapeutics has…
Intellia Therapeutics has temporarily paused dosing and screening in a pair of phase 3 trials in response to a liver safety signal. Shares in Intellia fell 45% to $14.01 in premarket trading.